Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan (Q73347788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

Déjosez M

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Ramp U

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Mahotka C

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Krieg A

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Walczak H

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Gabbert HE

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Gerharz CD

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

Cell Death & Differentiation

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1127-1136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.cdd.4400746

3 November 2019

exact match

0 references

cites work

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Identification of human cancers deficient in antigen processing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

To die or not to die: an overview of apoptosis and its role in disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

TRAIL: a molecule with multiple receptors and control mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

A novel receptor for Apo2L/TRAIL contains a truncated death domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Clinical implications of the p53 tumor-suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Characterization of two receptors for TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Apoptosis signaling by death receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

The tumor strikes back: new data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Enzyme and metabolic inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4400746

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4400746

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11139287%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference